Mendus AB (publ) (IMMU.ST)
IMMU.ST Stock Price Chart
Explore Mendus AB (publ) interactive price chart. Choose custom timeframes to analyze IMMU.ST price movements and trends.
IMMU.ST Company Profile
Discover essential business fundamentals and corporate details for Mendus AB (publ) (IMMU.ST) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
22 Apr 2013
Employees
28.00
Website
https://www.mendus.comCEO
Erik Manting
Description
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer. Its lead product is ilixadencel, which is in Phase II MERECA clinical trial for the treatment of kidney cancer; and Phase I/II clinical trial to treat liver cancer and gastrointestinal stromal tumors. The company's products also comprise DCP-001, which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia; and Phase I/II ALISON clinical trial for the treatment of ovarian cancers. It has a research collaboration with PCI Biotech Holding ASA for novel cancer vaccination treatment; and with Icahn School of Medicine at Mount Sinai. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden.
IMMU.ST Financial Timeline
Browse a chronological timeline of Mendus AB (publ) corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 11 Feb 2026
Upcoming earnings on 13 Nov 2025
Earnings released on 21 Aug 2025
Earnings released on 6 May 2025
EPS came in at -kr 0.61 falling short of the estimated -kr 0.54 by -13.49%.
Earnings released on 13 Feb 2025
EPS came in at -kr 0.63 surpassing the estimated -kr 0.72 by +12.50%, while revenue for the quarter reached kr 763.00K .
Earnings released on 8 Nov 2024
EPS came in at -kr 0.46 surpassing the estimated -kr 0.70 by +34.29%, while revenue for the quarter reached kr 876.00K .
Earnings released on 23 Aug 2024
EPS came in at -kr 0.76 falling short of the estimated -kr 0.62 by -22.58%, while revenue for the quarter reached kr 625.00K .
Stock split effective on 3 Jun 2024
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 17 May 2024
EPS came in at -kr 0.80 falling short of the estimated -kr 0.60 by -33.33%, while revenue for the quarter reached kr 2.78M .
Earnings released on 14 Feb 2024
EPS came in at -kr 1.12 , while revenue for the quarter reached kr 28.49M .
Earnings released on 9 Nov 2023
EPS came in at -kr 0.22 .
Earnings released on 29 Aug 2023
EPS came in at -kr 0.02 .
Stock split effective on 10 Jul 2023
Shares were split 217 : 200 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 12 May 2023
EPS came in at -kr 0.14 .
Earnings released on 17 Feb 2023
EPS came in at -kr 0.21 , while revenue for the quarter reached -kr 1.79M .
Earnings released on 11 Nov 2022
EPS came in at -kr 0.20 , while revenue for the quarter reached -kr 152.00K .
Earnings released on 26 Aug 2022
EPS came in at -kr 0.15 , while revenue for the quarter reached kr 35.00K .
Earnings released on 10 May 2022
EPS came in at -kr 0.14 , while revenue for the quarter reached kr 1.79M .
Earnings released on 17 Feb 2022
EPS came in at -kr 0.17 , while revenue for the quarter reached kr 6.00K .
Earnings released on 28 Oct 2021
EPS came in at -kr 0.18 .
Earnings released on 30 Sept 2021
EPS came in at -kr 0.12 .
Earnings released on 4 May 2021
EPS came in at -kr 0.23 , while revenue for the quarter reached kr 253.00K .
Earnings released on 18 Feb 2021
EPS came in at -kr 0.05 .
Earnings released on 5 Nov 2020
EPS came in at -kr 0.28 .
IMMU.ST Stock Performance
Access detailed IMMU.ST performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.